Search

Your search keyword '"Kaneko, Yudai"' showing total 41 results
Start Over Author "Kaneko, Yudai"
41 results on '"Kaneko, Yudai"'

1. Antibody-mimetic drug conjugate with efficient internalization activity using anti-HER2 VHH and duocarmycin

Author

Sakata, Juri, Tatsumi, Toshifumi, Sugiyama, Akira, Shimizu, Akihiro, Inagaki, Yuya, Katoh, Hiroto, Yamashita, Takefumi, Takahashi, Kazuki, Aki, Sho, Kaneko, Yudai, Kawamura, Takeshi, Miura, Mai, Ishii, Masazumi, Osawa, Tsuyoshi, Tanaka, Toshiya, Ishikawa, Shumpei, Tsukagoshi, Masanobu, Chansler, Michael, Kodama, Tatsuhiko, Kanai, Motomu, Tokuyama, Hidetoshi, and Yamatsugu, Kenzo

Published
2024
Full Text
View/download PDF

2. Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey

Author

Kobashi, Yurie, Kawamura, Takeshi, Shimazu, Yuzo, Zhao, Tianchen, Sugiyama, Akira, Nakayama, Aya, Kaneko, Yudai, Nishikawa, Yoshitaka, Omata, Fumiya, Takita, Morihito, Yamamoto, Chika, Yoshida, Makoto, Kosaka, Makoto, Murayama, Anju, Sugiura, Sota, Tanaka, Manato, Kawashima, Moe, Uchi, Yuna, Shindo, Joji, Oikawa, Tomoyoshi, Shibuya, Kenji, Kodama, Tatsuhiko, and Tsubokura, Masaharu

Published
2022
Full Text
View/download PDF

3. Antibody Profiling of Microbial Antigens in the Blood of COVID-19 mRNA Vaccine Recipients Using Microbial Protein Microarrays

Author

Saito, Hiroaki, primary, Yoshimura, Hiroki, additional, Yoshida, Makoto, additional, Tani, Yuta, additional, Kawashima, Moe, additional, Uchiyama, Taiga, additional, Zhao, Tianchen, additional, Yamamoto, Chika, additional, Kobashi, Yurie, additional, Sawano, Toyoaki, additional, Imoto, Seiya, additional, Park, Hyeongki, additional, Nakamura, Naotoshi, additional, Iwami, Shingo, additional, Kaneko, Yudai, additional, Nakayama, Aya, additional, Kodama, Tatsuhiko, additional, Wakui, Masatoshi, additional, Kawamura, Takeshi, additional, and Tsubokura, Masaharu, additional

Published
2023
Full Text
View/download PDF

4. Five doses of the mRNA vaccination potentially suppress ancestral-strain stimulated SARS-CoV2-specific cellular immunity: a cohort study from the Fukushima vaccination community survey, Japan

Author

Tani, Yuta, primary, Takita, Morihito, additional, Wakui, Masatoshi, additional, Saito, Hiroaki, additional, Nishiuchi, Takamitsu, additional, Zhao, Tianchen, additional, Yamamoto, Chika, additional, Kawamura, Takeshi, additional, Sugiyama, Akira, additional, Nakayama, Aya, additional, Kaneko, Yudai, additional, Kodama, Tatsuhiko, additional, Shinaha, Ryuzaburo, additional, and Tsubokura, Masaharu, additional

Published
2023
Full Text
View/download PDF

5. Varying Cellular Immune Response against SARS-CoV-2 after the Booster Vaccination: A Cohort Study from Fukushima Vaccination Community Survey, Japan

Author

Tani, Yuta, primary, Takita, Morihito, additional, Kobashi, Yurie, additional, Wakui, Masatoshi, additional, Zhao, Tianchen, additional, Yamamoto, Chika, additional, Saito, Hiroaki, additional, Kawashima, Moe, additional, Sugiura, Sota, additional, Nishikawa, Yoshitaka, additional, Omata, Fumiya, additional, Shimazu, Yuzo, additional, Kawamura, Takeshi, additional, Sugiyama, Akira, additional, Nakayama, Aya, additional, Kaneko, Yudai, additional, Kodama, Tetsuhiko, additional, Kami, Masahiro, additional, and Tsubokura, Masaharu, additional

Published
2023
Full Text
View/download PDF

6. Antibody and T-Cell Responses against SARS-CoV-2 after Booster Vaccination in Patients on Dialysis: A Prospective Observational Study

Author

Kawashima, Moe, primary, Saito, Hiroaki, additional, Nishiuchi, Takamitsu, additional, Yoshimura, Hiroki, additional, Wakui, Masatoshi, additional, Tani, Yuta, additional, Nishikawa, Yoshitaka, additional, Omata, Fumiya, additional, Takita, Morihito, additional, Zhao, Tianchen, additional, Yamamoto, Chika, additional, Kobashi, Yurie, additional, Kawamura, Takeshi, additional, Sugiyama, Akira, additional, Nakayama, Aya, additional, Kaneko, Yudai, additional, Sawano, Toyoaki, additional, Shibuya, Kenji, additional, Kazama, Junichiro, additional, Shineha, Ryuzaburo, additional, and Tsubokura, Masaharu, additional

Published
2023
Full Text
View/download PDF

7. Waning of Humoral Immunity and the Influencing Factors after BNT162b2 Vaccination: A Cohort Study with a Latent Growth Curve Model in Fukushima

Author

Kobashi, Yurie, primary, Takebayashi, Yoshitake, additional, Yoshida, Makoto, additional, Kawamura, Takeshi, additional, Shimazu, Yuzo, additional, Kaneko, Yudai, additional, Nishikawa, Yoshitaka, additional, Nakayama, Aya, additional, Takita, Morihito, additional, Zhao, Tianchen, additional, Yamamoto, Chika, additional, Ito, Naomi, additional, and Tsubokura, Masaharu, additional

Published
2022
Full Text
View/download PDF

8. Pathological complete remission of relapsed tumor by photo‐activating antibody–mimetic drug conjugate treatment

Author

Kaneko, Yudai, primary, Yamatsugu, Kenzo, additional, Yamashita, Takefumi, additional, Takahashi, Kazuki, additional, Tanaka, Toshiya, additional, Aki, Sho, additional, Tatsumi, Toshifumi, additional, Kawamura, Takeshi, additional, Miura, Mai, additional, Ishii, Masazumi, additional, Ohkubo, Kei, additional, Osawa, Tsuyoshi, additional, Kodama, Tatsuhiko, additional, Ishikawa, Shumpei, additional, Tsukagoshi, Masanobu, additional, Chansler, Michael, additional, Sugiyama, Akira, additional, Kanai, Motomu, additional, and Katoh, Hiroto, additional

Published
2022
Full Text
View/download PDF

9. What Proportion of Population has achieved Cellular Immunity against SARS-CoV-2 after Booster Vaccination: A Cross-sectional Study

Author

Tani, Yuta, primary, Takita, Morihito, additional, Kobashi, Yurie, additional, Wakui, Masatoshi, additional, Zhao, Tianchen, additional, Yamamoto, Chika, additional, Saito, Hiroaki, additional, Kawashima, Moe, additional, Sugiura, Sota, additional, Nishikawa, Yoshitaka, additional, Omata, Fumiya, additional, Shimazu, Yuzo, additional, Kawamura, Takeshi, additional, Sugiyama, Akira, additional, Nakayama, Aya, additional, Kaneko, Yudai, additional, Kodama, Tetsuhiko, additional, Kami, Masahiro, additional, and Tsubokura, Masaharu, additional

Published
2022
Full Text
View/download PDF

10. Waning of humoral immunity and affecting factors after BNT162b2 vaccination: a cohort study with latent growth curve model in Fukushima

Author

Kobashi, Yurie, primary, Takebayashi, Yoshitake, additional, Yoshida, Makoto, additional, Kawamura, Takeshi, additional, Shimazu, Yuzo, additional, Kaneko, Yudai, additional, Nishikawa, Yoshitaka, additional, Nakayama, Aya, additional, Takita, Morihiro, additional, Tianchen, Zhao, additional, Yamamoto, Chika, additional, Ito, Naomi, additional, and Tsubokura, Masaharu, additional

Published
2022
Full Text
View/download PDF

11. A personalized antibody score for predicting individual COVID-19 vaccine-elicited antibody levels from basic demographic and health information

Author

Nakamura, Naotoshi, primary, Park, Hyeongki, additional, Kim, Kwang Su, additional, Sato, Yoshitaka, additional, Jeong, Yong Dam, additional, Iwanami, Shoya, additional, Fujita, Yasuhisa, additional, Zhao, Tianchen, additional, Tani, Yuta, additional, Nishikawa, Yoshitaka, additional, Yamamoto, Chika, additional, Kobashi, Yurie, additional, Kawamura, Takeshi, additional, Sugiyama, Akira, additional, Nakayama, Aya, additional, Kaneko, Yudai, additional, Aihara, Kazuyuki, additional, Iwami, Shingo, additional, and Tsubokura, Masaharu, additional

Published
2022
Full Text
View/download PDF

12. Association of systemic adverse reaction patterns with long-term dynamics of humoral and cellular immunity after coronavirus disease 2019 third vaccination.

Author

Yoshida, Makoto, Kobashi, Yurie, Kawamura, Takeshi, Shimazu, Yuzo, Nishikawa, Yoshitaka, Omata, Fumiya, Saito, Hiroaki, Yamamoto, Chika, Zhao, Tianchen, Takita, Morihiro, Ito, Naomi, Tatsuno, Kenji, Kaneko, Yudai, Nakayama, Aya, Kodama, Tatsuhiko, Wakui, Masatoshi, Takahashi, Kenzo, and Tsubokura, Masaharu

Subjects
SARS-CoV-2, COVID-19, CELLULAR immunity, HUMORAL immunity, VACCINATION
Abstract

The objective of this study was to clarify the impact of adverse reactions on immune dynamics. We investigated the pattern of systemic adverse reactions after the second and third coronavirus disease 2019 (COVID-19) vaccinations and their relationship with immunoglobulin G against severe acute respiratory syndrome coronavirus 2 spike 1 protein titers, neutralizing antibody levels, peak cellular responses, and the rate of decrease after the third vaccination in a large-scale community-based cohort in Japan. Participants who received a third vaccination with BNT162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna), had two blood samples, had not had COVID-19, and had information on adverse reactions after the second and third vaccinations (n = 2198) were enrolled. We collected data on sex, age, adverse reactions, comorbidities, and daily medicine using a questionnaire survey. Participants with many systemic adverse reactions after the second and third vaccinations had significantly higher humoral and cellular immunity in the peak phase. Participants with multiple systemic adverse reactions after the third vaccination had small changes in the geometric values of humoral immunity and had the largest geometric mean of cellar immunity in the decay phase. Systemic adverse reactions after the third vaccination helped achieve high peak values and maintain humoral and cellular immunity. This information may help promote uptake of a third vaccination, even among those who hesitate due to adverse reactions. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, Japan

Author

Nakamura, Naotoshi, primary, Kobashi, Yurie, additional, Kim, Kwang Su, additional, Tani, Yuta, additional, Shimazu, Yuzo, additional, Zhao, Tianchen, additional, Nishikawa, Yoshitaka, additional, Omata, Fumiya, additional, Kawashima, Moe, additional, Yoshida, Makoto, additional, Abe, Toshiki, additional, Saito, Yoshika, additional, Senoo, Yuki, additional, Nonaka, Saori, additional, Takita, Morihito, additional, Yamamoto, Chika, additional, Kawamura, Takeshi, additional, Sugiyama, Akira, additional, Nakayama, Aya, additional, Kaneko, Yudai, additional, Park, Hyeongki, additional, Jeong, Yong Dam, additional, Tatematsu, Daiki, additional, Akao, Marwa, additional, Sato, Yoshitaka, additional, Iwanami, Shoya, additional, Fujita, Yasuhisa, additional, Wakui, Masatoshi, additional, Aihara, Kazuyuki, additional, Kodama, Tatsuhiko, additional, Shibuya, Kenji, additional, Iwami, Shingo, additional, and Tsubokura, Masaharu, additional

Published
2022
Full Text
View/download PDF

14. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine

Author

Kobashi, Yurie, primary, Shimazu, Yuzo, additional, Kawamura, Takeshi, additional, Nishikawa, Yoshitaka, additional, Omata, Fumiya, additional, Kaneko, Yudai, additional, Kodama, Tatsuhiko, additional, and Tsubokura, Masaharu, additional

Published
2022
Full Text
View/download PDF

15. The serological diversity of serum IgG/IgA/IgM against SARS‐CoV‐2 nucleoprotein, spike, and receptor‐binding domain and neutralizing antibodies in patients with COVID‐19 in Japan

Author

Kaneko, Yudai, primary, Sugiyama, Akira, additional, Tanaka, Toshiya, additional, Fukui, Kazushige, additional, Taguchi, Akashi, additional, Tatsuno, Kenji, additional, Nakayama, Aya, additional, Koga, Kazumasa, additional, Kishi, Yoshiro, additional, Daming, Wang, additional, Qian, Chungen, additional, Xia, Fuzhen, additional, He, Fan, additional, Zheng, Liang, additional, Yu, Yi, additional, Wada, Youichiro, additional, Wada, Yoshiaki, additional, Kodama, Tatsuhiko, additional, and Kawamura, Takeshi, additional

Published
2022
Full Text
View/download PDF

16. Antibody mimetic drug conjugate manufactured by high-yield Escherichia coli expression and non-covalent binding system

Author

Yamatsugu, Kenzo, primary, Katoh, Hiroto, additional, Yamashita, Takefumi, additional, Takahashi, Kazuki, additional, Aki, Sho, additional, Tatsumi, Toshifumi, additional, Kaneko, Yudai, additional, Kawamura, Takeshi, additional, Miura, Mai, additional, Ishii, Masazumi, additional, Ohkubo, Kei, additional, Osawa, Tsuyoshi, additional, Kodama, Tatsuhiko, additional, Ishikawa, Shumpei, additional, Kanai, Motomu, additional, and Sugiyama, Akira, additional

Published
2022
Full Text
View/download PDF

18. Factors Associated with COVID-19 Vaccine Booster Hesitancy: A Retrospective Cohort Study, Fukushima Vaccination Community Survey

Author

Yoshida, Makoto, primary, Kobashi, Yurie, additional, Kawamura, Takeshi, additional, Shimazu, Yuzo, additional, Nishikawa, Yoshitaka, additional, Omata, Fumiya, additional, Zhao, Tianchen, additional, Yamamoto, Chika, additional, Kaneko, Yudai, additional, Nakayama, Aya, additional, Takita, Morihito, additional, Ito, Naomi, additional, Kawashima, Moe, additional, Sugiura, Sota, additional, Shibuya, Kenji, additional, Iwami, Shingo, additional, Kim, Kwangsu, additional, Iwanami, Shoya, additional, Kodama, Tatsuhiko, additional, and Tsubokura, Masaharu, additional

Published
2022
Full Text
View/download PDF

19. Serologic Survey of IgG Against SARS-CoV-2 Among Hospital Visitors Without a History of SARS-CoV-2 Infection in Tokyo, 2020–2021

Author

Sanada, Takahiro, primary, Honda, Tomoko, additional, Yasui, Fumihiko, additional, Yamaji, Kenzaburo, additional, Munakata, Tsubasa, additional, Yamamoto, Naoki, additional, Kurano, Makoto, additional, Matsumoto, Yusuke, additional, Kohno, Risa, additional, Toyama, Sakiko, additional, Kishi, Yoshiro, additional, Horibe, Takuro, additional, Kaneko, Yudai, additional, Kakegawa, Mayumi, additional, Fukui, Kazushige, additional, Kawamura, Takeshi, additional, Daming, Wang, additional, Qian, Chungen, additional, Xia, Fuzhen, additional, He, Fan, additional, Yamasaki, Syudo, additional, Nishida, Atsushi, additional, Harada, Takayuki, additional, Higa, Masahiko, additional, Tokunaga, Yuko, additional, Takagi, Asako, additional, Itokawa, Masanari, additional, Kodama, Tatsuhiko, additional, and Kohara, Michinori, additional

Published
2022
Full Text
View/download PDF

21. The serological diversity of serum IgG/IgA/IgM against the SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan

Author

Kaneko, Yudai, primary, Sugiyama, Akira, additional, Tanaka, Toshiya, additional, Fukui, Kazushige, additional, Taguchi, Akashi, additional, Nakayama, Aya, additional, Koga, Kazumasa, additional, Kishi, Yoshiro, additional, Daming, Wang, additional, Qian, Chungen, additional, Xia, Fuzhen, additional, He, Fan, additional, Zheng, Liang, additional, Yu, Yi, additional, Wada, Youichiro, additional, Wada, Yoshiaki, additional, Kodama, Tatsuhiko, additional, and Kawamura, Takeshi, additional

Published
2021
Full Text
View/download PDF

24. CAMUIハイブリッドロケットの燃焼特性における形状効果

Author

Ito, Mitsunori, Maeda, Takenori, Kakikura, Akihito, Kaneko, Yudai, Mori, Kazuhiro, Totani, Tsuyoshi, Nagata, Harunori, and Uematsu, Tsutomu

Abstract

平成18年度宇宙輸送シンポジウム（2007年1月18日-19日. 宇宙航空研究開発機構宇宙科学研究本部）, 相模原市, 神奈川県, Space Transportation Symposium FY2006 (January 18-19, 2007. Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA)(ISAS)), Sagamihara, Kanagawa Japan, 資料番号: SA6000005038

Published
2007

34. Fuel Regression Rate Behavior of CAMUI Hybrid Rocket

Author

KANEKO, Yudai, primary, ITOH, Mitsunori, additional, KAKIKURA, Akihito, additional, MORI, Kazuhiro, additional, UEJIMA, Kenta, additional, NAKASHIMA, Takuji, additional, WAKITA, Masashi, additional, TOTANI, Tsuyoshi, additional, OSHIMA, Nobuyuki, additional, and NAGATA, Harunori, additional

Published
2009
Full Text
View/download PDF

40. Group of longitudinal adverse event patterns after the fourth dose of COVID-19 vaccination with a latent class analysis.

Author

Yamamoto C, Kobashi Y, Kawamura T, Nishikawa Y, Saito H, Oguro F, Zhao T, Takita M, Sawano T, Ozaki A, Abe T, Ito N, Kaneko Y, Nakayama A, Wakui M, Kodama T, and Tsubokura M

Subjects
Aged, Female, Humans, Male, Middle Aged, Japan, Latent Class Analysis, Longitudinal Studies, Surveys and Questionnaires, Vaccination adverse effects, COVID-19 prevention & control, COVID-19 Vaccines adverse effects, COVID-19 Vaccines administration & dosage
Abstract

Introduction: Vaccination has been implemented as a useful measure to combat the COVID-19 pandemic. However, there is a tendency for individuals to avoid vaccination due to the possibility of adverse events, making it important to investigate the relationship between COVID-19 vaccines and their adverse events. This study explored longitudinal adverse event patterns and factors that influence adverse events following the second to fourth doses of the COVID-19 vaccine through a latent class analysis., Methods: Participants were recruited from the Fukushima Prefecture and included individuals who had completed four doses of the COVID-19 mRNA vaccine. This study utilized data from questionnaire surveys and blood collection conducted between September 2021 and November 2022. In the questionnaire, factors such as sex, age, medical history, medication, type of vaccine administered, and adverse events following vaccination were recorded. Additionally, in the blood data, serological tests [IgG(S)] and cellular immune responses (T-spot) were measured. Descriptive statistics, latent class analysis, multivariable logistic regression, and multiple regression analyses were performed to identify the longitudinal adverse event patterns and influencing factors. By analyzing adverse events over time, we identified two distinct groups: those less prone to experiencing adverse events (Group 1) and those more susceptible (Group 2) to latent class analysis., Results: A total of 1,175 participants were included after excluding those without any adverse events. The median age of the participants in Group 1 was 70 years, and in Group 2 it was 51 years. The proportion of female participants was 298 in Group 1 and 353 in Group 2. Patients in Group 2 were significantly younger ( p  < 0.001) and more likely to be female ( p  < 0.001) than those in Group 1. Furthermore, the median IgG(S) value after the fourth vaccination was 3,233 AU/mL in Group 1 and 4,059.39 AU/mL in Group 2. The median T-spot value was 15.4 in Group 1 and 28.5 in Group 2. Group 2 showed significantly higher IgG(S) and T-spot values after the fourth vaccination ( p  < 0.001)., Discussion: Our findings suggest that factors other than age, particularly sex and a history of allergies, significantly influence the likelihood of experiencing adverse events. Groups categorized by latent class analysis for longitudinal adverse events are expected to be valuable for optimizing vaccination strategies and formulating public health measures., Competing Interests: YKa was hired by Medical & Biological Laboratories Co. (MBL, Tokyo, Japan). MBL imported the test materials used in the study. YKa participated in the testing process; however, he did not engage in the research design and analysis. YKo and MTs received a grant from the Pfizer Health Research Foundation for research that was not associated with this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Yamamoto, Kobashi, Kawamura, Nishikawa, Saito, Oguro, Zhao, Takita, Sawano, Ozaki, Abe, Ito, Kaneko, Nakayama, Wakui, Kodama and Tsubokura.)

Published
2024
Full Text
View/download PDF

41. Modeling and predicting individual variation in COVID-19 vaccine-elicited antibody response in the general population.

Author

Nakamura N, Kobashi Y, Kim KS, Park H, Tani Y, Shimazu Y, Zhao T, Nishikawa Y, Omata F, Kawashima M, Yoshida M, Abe T, Saito Y, Senoo Y, Nonaka S, Takita M, Yamamoto C, Kawamura T, Sugiyama A, Nakayama A, Kaneko Y, Jeong YD, Tatematsu D, Akao M, Sato Y, Iwanami S, Fujita Y, Wakui M, Aihara K, Kodama T, Shibuya K, Iwami S, and Tsubokura M

Abstract

As we learned during the COVID-19 pandemic, vaccines are one of the most important tools in infectious disease control. To date, an unprecedentedly large volume of high-quality data on COVID-19 vaccinations have been accumulated. For preparedness in future pandemics beyond COVID-19, these valuable datasets should be analyzed to best shape an effective vaccination strategy. We are collecting longitudinal data from a community-based cohort in Fukushima, Japan, that consists of 2,407 individuals who underwent serum sampling two or three times after a two-dose vaccination with either BNT162b2 or mRNA-1273. Using the individually reconstructed time courses of the vaccine-elicited antibody response based on mathematical modeling, we first identified basic demographic and health information that contributed to the main features of the antibody dynamics, i.e., the peak, the duration, and the area under the curve. We showed that these three features of antibody dynamics were partially explained by underlying medical conditions, adverse reactions to vaccinations, and medications, consistent with the findings of previous studies. We then applied to these factors a recently proposed computational method to optimally fit an "antibody score", which resulted in an integer-based score that can be used as a basis for identifying individuals with higher or lower antibody titers from basic demographic and health information. The score can be easily calculated by individuals themselves or by medical practitioners. Although the sensitivity of this score is currently not very high, in the future, as more data become available, it has the potential to identify vulnerable populations and encourage them to get booster vaccinations. Our mathematical model can be extended to any kind of vaccination and therefore can form a basis for policy decisions regarding the distribution of booster vaccines to strengthen immunity in future pandemics., Competing Interests: YKaneko is employed by Medical & Biological Laboratories, Co. (MBL, Tokyo, Japan). MBL imported the testing material used in this research. YKaneko participated in the testing process; however, he did not engage in the research design and analysis. YKobashi and MT received a research grant from Pfizer Health Research Foundation for research not associated with this work., (Copyright: © 2024 Nakamura et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results